• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Dianthus Therapeutics Inc.

    11/14/24 5:47:35 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DNTH alert in real time by email
    SC 13G/A 1 tm2428137d6_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Dianthus Therapeutics, Inc.

    (Name of Issuer)

     

    Common stock, $0.001 par value per share

    (Title of Class of Securities)

     

    252828108

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
       
    x Rule 13d-1(c)
       
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 252828108 Page 2 of 14

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)    (b) ¨

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,744,373 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,744,373 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,744,373 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.9% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
      
    (2)Consists of (i) 132,469 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,244 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,598,660 shares held by Venrock Healthcare Capital Partners EG, L.P.
      
    (3)This percentage is calculated based upon 29,366,352 shares of Common Stock outstanding as of September 24, 2024, as reported in the Issuer’s prospectus supplement dated October 11, 2024 filed with the Securities and Exchange Commission (the “SEC”) on October 11, 2024.

     

     

     

     

    CUSIP No. 252828108 Page 3 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)    (b) ¨

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,744,373 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,744,373 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,744,373 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.9% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
      
    (2)Consists of (i) 132,469 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,244 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,598,660 shares held by Venrock Healthcare Capital Partners EG, L.P.
      
    (3)This percentage is calculated based upon 29,366,352 shares of Common Stock outstanding as of September 24, 2024, as reported in the Issuer’s prospectus supplement dated October 11, 2024 filed with the SEC on October 11, 2024.

     

     

     

     

    CUSIP No. 252828108 Page 4 of 14

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)    (b) ¨

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,744,373 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,744,373 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,744,373 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.9% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
      
    (2)Consists of (i) 132,469 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,244 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,598,660 shares held by Venrock Healthcare Capital Partners EG, L.P.
      
    (3)This percentage is calculated based upon 29,366,352 shares of Common Stock outstanding as of September 24, 2024, as reported in the Issuer’s prospectus supplement dated October 11, 2024 filed with the SEC on October 11, 2024.

     

     

     

     

    CUSIP No. 252828108 Page 5 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)     (b) ¨

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,744,373 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,744,373 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,744,373 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.9% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
      
    (2)Consists of (i) 132,469 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,244 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,598,660 shares held by Venrock Healthcare Capital Partners EG, L.P.
      
    (3)This percentage is calculated based upon 29,366,352 shares of Common Stock outstanding as of September 24, 2024, as reported in the Issuer’s prospectus supplement dated October 11, 2024 filed with the SEC on October 11, 2024.

     

     

     

     

    CUSIP No. 252828108 Page 6 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)    (b) ¨

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,744,373 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,744,373 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,744,373 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.9% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
      
    (2)Consists of (i) 132,469 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,244 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,598,660 shares held by Venrock Healthcare Capital Partners EG, L.P.
      
    (3)This percentage is calculated based upon 29,366,352 shares of Common Stock outstanding as of September 24, 2024, as reported in the Issuer’s prospectus supplement dated October 11, 2024 filed with the SEC on October 11, 2024.

     

     

     

     

    CUSIP No. 252828108 Page 7 of 14

     

    1.

    Names of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)     (b) ¨

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,744,373 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,744,373 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,744,373 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.9% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
      
    (2)Consists of (i) 132,469 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,244 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,598,660 shares held by Venrock Healthcare Capital Partners EG, L.P.
      
    (3)This percentage is calculated based upon 29,366,352 shares of Common Stock outstanding as of September 24, 2024, as reported in the Issuer’s prospectus supplement dated October 11, 2024 filed with the SEC on October 11, 2024.

     

     

     

     

    CUSIP No. 252828108 Page 8 of 14

     

    1.

    Names of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)     (b) ¨

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,744,373 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,744,373 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,744,373 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.9% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
      
    (2)Consists of (i) 132,469 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,244 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,598,660 shares held by Venrock Healthcare Capital Partners EG, L.P.
      
    (3)This percentage is calculated based upon 29,366,352 shares of Common Stock outstanding as of September 24, 2024, as reported in the Issuer’s prospectus supplement dated October 11, 2024 filed with the SEC on October 11, 2024.

     

     

     

     

    CUSIP No. 252828108 Page 9 of 14

     

    Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of the Common Stock of Dianthus Therapeutics, Inc.

     

    Item 1.
      (a)

    Name of Issuer

     

    Dianthus Therapeutics, Inc.

     
      (b)

    Address of Issuer’s Principal Executive Offices

     

    7 Times Square, 43rd Floor

    New York, NY 10036

     
    Item 2.
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence

     

      New York Office: Palo Alto Office:
         
      7 Bryant Park 3340 Hillview Avenue
      23rd Floor Palo Alto, CA 94304
      New York, NY 10018

     

      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

     

    Common Stock, $0.001 par value

     
      (e)

    CUSIP Number

     

    252828108

     

     

     

     

    CUSIP No. 252828108 Page 10 of 14

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      
     Not applicable

     

    Item 4. Ownership  
         
      (a) Amount beneficially owned as of September 30, 2024:  
               
            Venrock Healthcare Capital Partners III, L.P. 1,744,373  (1)  
            VHCP Co-Investment Holdings III, LLC 1,744,373  (1)  
            Venrock Healthcare Capital Partners EG, L.P. 1,744,373  (1)  
            VHCP Management III, LLC 1,744,373  (1)  
            VHCP Management EG, LLC 1,744,373  (1)  
            Nimish Shah 1,744,373  (1)  
            Bong Koh 1,744,373  (1)  
       
      (b) Percent of class as of September 30, 2024:  
               
            Venrock Healthcare Capital Partners III, L.P. 5.9%  (2)  
            VHCP Co-Investment Holdings III, LLC 5.9%  (2)  
            Venrock Healthcare Capital Partners EG, L.P. 5.9%  (2)  
            VHCP Management III, LLC 5.9%  (2)  
            VHCP Management EG, LLC 5.9%  (2)  
            Nimish Shah 5.9%  (2)  
            Bong Koh 5.9%  (2)  
       
      (c) Number of shares as to which the person has, as of September 30, 2024:  
               
        (i) Sole power to vote or to direct the vote:  
                 
            Venrock Healthcare Capital Partners III, L.P. 0  
            VHCP Co-Investment Holdings III, LLC 0  
            Venrock Healthcare Capital Partners EG, L.P. 0  
            VHCP Management III, LLC 0  
            VHCP Management EG, LLC 0  
            Nimish Shah 0  
            Bong Koh 0  

     

     

     

     

    CUSIP No. 252828108 Page 11 of 14

     

        (ii) Shared power to vote or to direct the vote:  
                 
            Venrock Healthcare Capital Partners III, L.P. 1,744,373  (1)  
            VHCP Co-Investment Holdings III, LLC 1,744,373  (1)  
            Venrock Healthcare Capital Partners EG, L.P. 1,744,373  (1)  
            VHCP Management III, LLC 1,744,373  (1)  
            VHCP Management EG, LLC 1,744,373  (1)  
            Nimish Shah 1,744,373  (1)  
            Bong Koh 1,744,373  (1)  

     

        (iii) Sole power to dispose or to direct the disposition of:  
             
            Venrock Healthcare Capital Partners III, L.P. 0  
            VHCP Co-Investment Holdings III, LLC 0  
            Venrock Healthcare Capital Partners EG, L.P. 0  
            VHCP Management III, LLC 0  
            VHCP Management EG, LLC 0  
            Nimish Shah 0  
            Bong Koh 0  
       
        (iv) Shared power to dispose or to direct the disposition of:  
             
            Venrock Healthcare Capital Partners III, L.P. 1,744,373  (1)  
            VHCP Co-Investment Holdings III, LLC 1,744,373  (1)  
            Venrock Healthcare Capital Partners EG, L.P. 1,744,373  (1)  
            VHCP Management III, LLC 1,744,373  (1)  
            VHCP Management EG, LLC 1,744,373  (1)  
            Nimish Shah 1,744,373  (1)  
            Bong Koh 1,744,373  (1)  
       

     

      (1) Consists of (i) 132,469 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,244 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,598,660 shares held by Venrock Healthcare Capital Partners EG, L.P. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
       
      (2) This percentage is calculated based upon 29,366,352 shares of Common Stock outstanding as of September 24, 2024, as reported in the Issuer’s prospectus supplement dated October 11, 2024 filed with the SEC on October 11, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨

     

     

     

     

    CUSIP No. 252828108 Page 12 of 14

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
     
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP No. 252828108 Page 13 of 14

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

    VHCP Co-Investment Holdings III, LLC    
         
    By: VHCP Management III, LLC    
    Its: Manager    
         
    By: /s/ Sherman G. Souther    
      Name: Sherman G. Souther    
      Its: Authorized Signatory    

     

    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    
         
    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    

     

     

     

     

    CUSIP No. 252828108 Page 14 of 14

     

    EXHIBITS

     

    A: Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on September 21, 2023)
     
    B: Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed September 21, 2023)
     
    C: Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on September 21, 2023)

     

     

     

    Get the next $DNTH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNTH

    DatePrice TargetRatingAnalyst
    7/2/2025Outperform
    William Blair
    12/20/2024Buy
    TD Cowen
    10/3/2024$48.00Outperform
    Oppenheimer
    7/26/2024$58.00Outperform
    Robert W. Baird
    6/27/2024Overweight
    Cantor Fitzgerald
    5/16/2024$40.00Buy
    H.C. Wainwright
    2/15/2024$44.00Buy
    Stifel
    12/26/2023$22.00Buy
    Jefferies
    More analyst ratings

    $DNTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases ("Dianthus" or the "Company"), today announced that it closed its previously announced underwritten public offering of 7,627,879 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 1,140,000 shares, at a public offering price of $33.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,112,121 shares of its common stoc

    9/11/25 4:07:28 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

    NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases ("Dianthus" or the "Company"), today announced the pricing of its previously announced upsized underwritten public offering of 6,487,879 shares of its common stock at a public offering price per share of $33.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,112,121 shares of its common stock at a public offering price of $32.999 per pre-funded warrant. The pre-funded warrants have an exerci

    9/9/25 10:35:49 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

    NEW YORK and WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases ("Dianthus" or the "Company"), today announced that it has commenced an underwritten public offering of $150 million of its shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Dianthus expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its shares of common stock at the public

    9/8/25 4:00:01 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO & CBO Savitz Ryan exercised 20,000 shares at a strike of $8.44 and sold $700,000 worth of shares (20,000 units at $35.00) (SEC Form 4)

    4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

    9/11/25 5:20:43 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Violin Jonathan

    4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

    5/22/25 4:44:50 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Soteropoulos Paula

    4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

    5/22/25 4:43:34 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Dianthus Therapeutics

    William Blair initiated coverage of Dianthus Therapeutics with a rating of Outperform

    7/2/25 8:17:26 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Dianthus Therapeutics

    TD Cowen initiated coverage of Dianthus Therapeutics with a rating of Buy

    12/20/24 7:31:45 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Dianthus Therapeutics with a new price target

    Oppenheimer initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $48.00

    10/3/24 7:28:24 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    SEC Filings

    View All

    SEC Form 8-K filed by Dianthus Therapeutics Inc.

    8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

    9/11/25 7:20:07 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Dianthus Therapeutics Inc.

    424B5 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

    9/10/25 7:53:23 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Dianthus Therapeutics Inc.

    424B5 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

    9/8/25 4:12:17 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Dianthus Therapeutics Inc.

    SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

    12/3/24 9:19:18 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Dianthus Therapeutics Inc.

    SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

    11/22/24 4:41:50 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dianthus Therapeutics Inc.

    SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

    11/14/24 5:48:32 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    Financials

    Live finance-specific insights

    View All

    Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile

    Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at Week 13 Claseprubart demonstrated a rapid and sustained onset of action, with both doses achieving statistically significant improvements in MG-ADL and QMG scores at Week 1 Claseprubart 300mg Q2W dose was also statistically significant and clinically meaningful across other key efficacy endpoints, including Minimal Symptom Expression (MSE), Myasthenia Gravis Composite (MGC) Score and the Myasthenia Gravis Quality of Life Scale (MG-QoL-15r) Bot

    9/8/25 7:00:00 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

    NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT. Investor Webcast & Conference Call InformationTo access the live conference call by phone, please register here. Conference call participants in the question and answer session should pre-register to receive

    9/7/25 6:25:00 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    Leadership Updates

    Live Leadership Updates

    View All

    Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors

    Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Simon Read, Ph.D., to the Company's Board of Directors. Dr. Read is a serial entrepreneur with more than 30 years of biopharmaceutical experi

    5/22/25 4:10:00 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors

    Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion Mr. King also led the commercial strategy behind the first FDA-approved, self-administered, subcutaneous biologic for gMG as the Chief Commercial Officer of Ra Pharma, acquired by UCB for $2.5 billion Mr. Kango has >26 years of industry experience spanning senior executive, commercial and business development roles in the pharmaceutical and biotechnology sector NEW YORK and WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology co

    3/5/25 7:00:00 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer

    Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President, Head of Investor Relations & Corporate Affairs with over 20 years of experience at leading public biopharmaceutical companies NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr.

    11/29/23 4:05:00 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care